Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04774952 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | PHASE1 | COMPLETED | 58 | — | — | Apr 7, 2021 | Jun 28, 2024 | Apr 15, 2025 | 8 | United States |
Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy
Incidence and nature of DLTs with RMC-5552 monotherapy
| Arm | Type | Description |
|---|---|---|
| RMC-5552 | EXPERIMENTAL | RMC-5552 for IV administration |
| Name | Type | Description |
|---|---|---|
| RMC-5552 | DRUG | RMC-5552 for IV administration |
Inclusion Criteria: * Participants (male or female) ≥18 years of age * Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments including approved drugs for oncogenic drivers in their tumor type * Easter...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |